Client ExpansionOne of its largest biopharma clients has expanded its commitment to OPRX with a multi-solution, multi-brand program.
EarningsDespite the CEO's resignation, the company expects its 2024 numbers to be at the higher end of the guidance ranges for revenue and AEBITDA.
Growth OpportunitiesThe fundamentals of the company remain strong, with management seeing solid growth opportunities in the DAAP space and experiencing good traction during the Q4 RFP season.